DaunorubicinCytarabineIdarubicinAntibiotics, AntineoplasticLeukemia, Myeloid, AcuteRemission InductionNaphthacenesMitoxantroneAntineoplastic Combined Chemotherapy ProtocolsConsolidation ChemotherapyLeukemia, MyeloidThioguanineP-GlycoproteinDoxorubicinEtoposideAntimetabolites, AntineoplasticAnthracyclinesVincristineArabinonucleosidesDrug Resistance, MultipleAclarubicinDrug Administration ScheduleAsparaginaseInduction ChemotherapyLeukemia P388Drug AgonismPrecursor Cell Lymphoblastic Leukemia-LymphomaDrug ResistanceVerapamilMethotrexateCyclosporinsDrug Resistance, NeoplasmAcute DiseaseTreatment Outcome6-MercaptopurineLeukemia, Myelomonocytic, AcuteAntineoplastic AgentsCarcinoma, Ehrlich TumorRazoxaneLeukemiaLiposomesAmsacrineHL-60 CellsDisease-Free SurvivalSurvival AnalysisMeningeal CarcinomatosisLymphoma, Non-HodgkinStreptomycesInjections, SpinalLeukemic InfiltrationCyclophosphamideSurvival RateDrug Screening Assays, AntitumorTeniposideDose-Response Relationship, DrugRecurrenceTumor Cells, CulturedCytidine MonophosphateCarmustinePrednisoneDeoxycytidine KinaseArabinonucleotidesInfusions, IntravenousLeukemia, Promyelocytic, AcuteDrug SynergismBlast CrisisMultidrug Resistance-Associated ProteinsCombined Modality TherapyLeukemia, Myeloid, Accelerated PhasePyrazolonesAnthraquinonesCentral Nervous System NeoplasmsPrognosisSalvage TherapyVidarabineK562 CellsArabinofuranosylcytosine TriphosphateTransplantation, AutologousGenes, MDRLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAminoglycosidesRhodamine 123Anemia, Refractory, with Excess of BlastsCell SurvivalMyelodysplastic SyndromesBenzylisoquinolinesDexamethasoneGene Expression Regulation, Leukemic